Browsing Tag
ruxolitinib
6 posts
Karyopharm Therapeutics (KPTI) tees up ASCO 2026 readout as SENTRY trial shifts myelofibrosis debate
Karyopharm is taking its Phase 3 SENTRY myelofibrosis data to ASCO 2026. Read why the late-breaking slot matters for KPTI and selinexor now.
April 21, 2026
FDA extends deadline for Incyte’s Opzelura cream review in pediatric eczema following submission of new manufacturing data
Incyte (NASDAQ: INCY) faces FDA review delay for Opzelura® cream in children aged 2–11 with eczema, following CMC data submission. Decision now due September 2025.
June 25, 2025
Novartis announces takeover bid for MorphoSys AG to boost oncology pipeline
In a significant move within the pharmaceutical industry, Novartis has entered into an agreement to launch a voluntary…
February 6, 2024
Incyte’s Ruxolitinib Cream demonstrates promising efficacy in TRuE-AD3 study
Incyte (Nasdaq:INCY), an esteemed biopharmaceutical giant, has unveiled compelling expanded findings from its Phase 3 TRuE-AD3 study on…
October 15, 2023
Incyte bags Opzelura EC approval for treatment of non-segmental vitiligo
Incyte has secured marketing authorization for Opzelura (ruxolitinib) cream 15mg/g from the European Commission (EC) for non-segmental vitiligo…
April 23, 2023
US biopharma company Incyte bags Opzelura FDA approval for vitiligo
Opzelura FDA approval for vitiligo : Incyte has secured approval for Opzelura (ruxolitinib) cream 1.5% from the US…
July 24, 2022